The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
The University of Texas MD Anderson Cancer Center · Feinstein Institute for Medical Research · +1 more institution
Abstract
B-cell receptor (BCR) signaling is a critical pathway in the pathogenesis of several B-cell malignancies, including chronic lymphocytic leukemia (CLL), and can be targeted by inhibitors of BCR-associated kinases, such as Bruton tyrosine kinase (Btk). PCI-32765, a selective, irreversible Btk inhibitor, is a novel, molecularly targeted agent for patients with B-cell malignancies, and is particularly active in patients with CLL. In this study, we analyzed the mechanism of action of PCI-32765 in CLL, using in vitro and in vivo models, and performed correlative studies on specimens from patients receiving therapy with PCI-32765. PCI-32765 significantly inhibited CLL cell survival, DNA synthesis, and migration in…
Citation impact
- FWCI
- 25.02
- Percentile
- 100%
- References
- 39
Authors
10- SPSabine PonaderCorresponding
The University of Texas MD Anderson Cancer Center
- SCShih‐Shih Chen
Feinstein Institute for Medical Research
- JJJoseph J. Buggy
Pharmacyclics (United States)
- KBKumudha Balakrishnan
The University of Texas MD Anderson Cancer Center
- VGVarsha Gandhi
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Bruton's tyrosine kinase
- Chronic lymphocytic leukemia
- Cancer research
- Ibrutinib
- Immunology
- Biology
- Idelalisib
- In vivo